Jan. 28 at 10:03 PM
$QNRX I've been crunching future sales from FDA approved med for Netherton Syndrome. There are currently no FDA approve drug and QNRX is set to be the first. There are approximately 7000 people with this disease in the US, EU, and Japan combined. Typical topical drugs for rare diseases are priced around
$25,000 to
$30,000 per month, which comes out to
$300,000 to
$360,000 a year per person. That's
$2.1 Billion to
$2.5 billion in sales. Then there's the sales to the rest of the world, which of course will be priced much lower but add significantly to the total sales. Drugs for rare diseases typically have 80% profit margins.
